Association Between Blood Pressure and Cardiovascular Outcomes in Liver Transplant Recipients.

Association Between Blood Pressure and Cardiovascular Outcomes in Liver Transplant Recipients.

Liver transplantation extends life in over 8,000 patients in the United States each year. However, heart disease is a leading cause of complications after liver transplantation. One in three liver transplant recipients will experience a heart disease complication within 1 year of transplant. Heart disease complications are potentially preventable through identification and treatment of heart disease risk factors, such as high blood pressure. Medications that prevent rejection of the liver graft contribute to high blood pressure after transplant. In fact, up to 90% of liver transplant recipients will have high blood pressure within 6 years of liver transplant. Thus, one way to prevent heart disease complications after liver transplant might be to lower blood pressure by reducing exposure to these types of medications. The goal of this study is to evaluate the relationship between blood pressure and heart disease outcomes taking into consideration the types of anti-rejection medications that patients have been exposed to.

[{ "PostingID": 4141, "Title": "NOVARTIS-CRAD001H2304", "Description": "A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients" },{ "PostingID": 20037, "Title": "NOVARTIS-CRAD001HDE10", "Description": "Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients" }]